EGFR and non-small cell lung carcinoma: The identification of EGFR mutations and ALK rearrangements as actionable oncogenic drivers in NSCLC has revolutionized the treatment approach for patients with advanced‐stage disease, leading to a biomarker‐driven therapeutic paradigm [61].